Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-nNaive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1
CONCLUSION: Our findings provide data for treatment and resistance management of INSTIs and may provide feedback for INSTIs resistance surveillance consensus-building efforts. In viral rebound under INSTI treatment, INSTI-resistant mutations follow typical INSTI resistance pathways and high resistance rates. INSTI resistance genotypic analysis should be considered before any DTG-based regimes can be initiated in the future, and reduced DTG susceptibility should be carefully monitored and investigated.PMID:35240975 | DOI:10.2174/1570162X20666220303104509 (Source: Current HIV Research)
Source: Current HIV Research - March 4, 2022 Category: Infectious Diseases Authors: Murat Sayan Figen Sarigul Yildirim Sila Akhan Ilkay Karaoglan Halis Akalin Source Type: research
Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-nNaive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1
CONCLUSION: Our findings provide data for treatment and resistance management of INSTIs and may provide feedback for INSTIs resistance surveillance consensus-building efforts. In viral rebound under INSTI treatment, INSTI-resistant mutations follow typical INSTI resistance pathways and high resistance rates. INSTI resistance genotypic analysis should be considered before any DTG-based regimes can be initiated in the future, and reduced DTG susceptibility should be carefully monitored and investigated.PMID:35240975 | DOI:10.2174/1570162X20666220303104509 (Source: Current HIV Research)
Source: Current HIV Research - March 4, 2022 Category: Infectious Diseases Authors: Murat Sayan Figen Sarigul Yildirim Sila Akhan Ilkay Karaoglan Halis Akalin Source Type: research
Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-nNaive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1
CONCLUSION: Our findings provide data for treatment and resistance management of INSTIs and may provide feedback for INSTIs resistance surveillance consensus-building efforts. In viral rebound under INSTI treatment, INSTI-resistant mutations follow typical INSTI resistance pathways and high resistance rates. INSTI resistance genotypic analysis should be considered before any DTG-based regimes can be initiated in the future, and reduced DTG susceptibility should be carefully monitored and investigated.PMID:35240975 | DOI:10.2174/1570162X20666220303104509 (Source: Current HIV Research)
Source: Current HIV Research - March 4, 2022 Category: Infectious Diseases Authors: Murat Sayan Figen Sarigul Yildirim Sila Akhan Ilkay Karaoglan Halis Akalin Source Type: research
Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-nNaive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1
CONCLUSION: Our findings provide data for treatment and resistance management of INSTIs and may provide feedback for INSTIs resistance surveillance consensus-building efforts. In viral rebound under INSTI treatment, INSTI-resistant mutations follow typical INSTI resistance pathways and high resistance rates. INSTI resistance genotypic analysis should be considered before any DTG-based regimes can be initiated in the future, and reduced DTG susceptibility should be carefully monitored and investigated.PMID:35240975 | DOI:10.2174/1570162X20666220303104509 (Source: Current HIV Research)
Source: Current HIV Research - March 4, 2022 Category: Infectious Diseases Authors: Murat Sayan Figen Sarigul Yildirim Sila Akhan Ilkay Karaoglan Halis Akalin Source Type: research
Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-nNaive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1
CONCLUSION: Our findings provide data for treatment and resistance management of INSTIs and may provide feedback for INSTIs resistance surveillance consensus-building efforts. In viral rebound under INSTI treatment, INSTI-resistant mutations follow typical INSTI resistance pathways and high resistance rates. INSTI resistance genotypic analysis should be considered before any DTG-based regimes can be initiated in the future, and reduced DTG susceptibility should be carefully monitored and investigated.PMID:35240975 | DOI:10.2174/1570162X20666220303104509 (Source: Current HIV Research)
Source: Current HIV Research - March 4, 2022 Category: Infectious Diseases Authors: Murat Sayan Figen Sarigul Yildirim Sila Akhan Ilkay Karaoglan Halis Akalin Source Type: research
Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-nNaive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1
CONCLUSION: Our findings provide data for treatment and resistance management of INSTIs and may provide feedback for INSTIs resistance surveillance consensus-building efforts. In viral rebound under INSTI treatment, INSTI-resistant mutations follow typical INSTI resistance pathways and high resistance rates. INSTI resistance genotypic analysis should be considered before any DTG-based regimes can be initiated in the future, and reduced DTG susceptibility should be carefully monitored and investigated.PMID:35240975 | DOI:10.2174/1570162X20666220303104509 (Source: Current HIV Research)
Source: Current HIV Research - March 4, 2022 Category: Infectious Diseases Authors: Murat Sayan Figen Sarigul Yildirim Sila Akhan Ilkay Karaoglan Halis Akalin Source Type: research
Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-nNaive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1
CONCLUSION: Our findings provide data for treatment and resistance management of INSTIs and may provide feedback for INSTIs resistance surveillance consensus-building efforts. In viral rebound under INSTI treatment, INSTI-resistant mutations follow typical INSTI resistance pathways and high resistance rates. INSTI resistance genotypic analysis should be considered before any DTG-based regimes can be initiated in the future, and reduced DTG susceptibility should be carefully monitored and investigated.PMID:35240975 | DOI:10.2174/1570162X20666220303104509 (Source: Current HIV Research)
Source: Current HIV Research - March 4, 2022 Category: Infectious Diseases Authors: Murat Sayan Figen Sarigul Yildirim Sila Akhan Ilkay Karaoglan Halis Akalin Source Type: research
Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-nNaive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1
CONCLUSION: Our findings provide data for treatment and resistance management of INSTIs and may provide feedback for INSTIs resistance surveillance consensus-building efforts. In viral rebound under INSTI treatment, INSTI-resistant mutations follow typical INSTI resistance pathways and high resistance rates. INSTI resistance genotypic analysis should be considered before any DTG-based regimes can be initiated in the future, and reduced DTG susceptibility should be carefully monitored and investigated.PMID:35240975 | DOI:10.2174/1570162X20666220303104509 (Source: Current HIV Research)
Source: Current HIV Research - March 4, 2022 Category: Infectious Diseases Authors: Murat Sayan Figen Sarigul Yildirim Sila Akhan Ilkay Karaoglan Halis Akalin Source Type: research
Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-nNaive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1
CONCLUSION: Our findings provide data for treatment and resistance management of INSTIs and may provide feedback for INSTIs resistance surveillance consensus-building efforts. In viral rebound under INSTI treatment, INSTI-resistant mutations follow typical INSTI resistance pathways and high resistance rates. INSTI resistance genotypic analysis should be considered before any DTG-based regimes can be initiated in the future, and reduced DTG susceptibility should be carefully monitored and investigated.PMID:35240975 | DOI:10.2174/1570162X20666220303104509 (Source: Current HIV Research)
Source: Current HIV Research - March 4, 2022 Category: Infectious Diseases Authors: Murat Sayan Figen Sarigul Yildirim Sila Akhan Ilkay Karaoglan Halis Akalin Source Type: research
Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-nNaive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1
CONCLUSION: Our findings provide data for treatment and resistance management of INSTIs and may provide feedback for INSTIs resistance surveillance consensus-building efforts. In viral rebound under INSTI treatment, INSTI-resistant mutations follow typical INSTI resistance pathways and high resistance rates. INSTI resistance genotypic analysis should be considered before any DTG-based regimes can be initiated in the future, and reduced DTG susceptibility should be carefully monitored and investigated.PMID:35240975 | DOI:10.2174/1570162X20666220303104509 (Source: Current HIV Research)
Source: Current HIV Research - March 4, 2022 Category: Infectious Diseases Authors: Murat Sayan Figen Sarigul Yildirim Sila Akhan Ilkay Karaoglan Halis Akalin Source Type: research
Integrase Inhibitors are Associated with Neuropsychiatric Symptoms in Women with HIV
AbstractObjectiveWomen with HIV(WWH) are more likely to discontinue/change antiretroviral therapy(ART) due to side effects including neuropsychiatric symptoms. Efavirenz and integrase strand transfer inhibitors(INSTIs) are particularly concerning. We focused on these ART agents and neuropsychiatric symptoms in previously developed subgroups of WWH that differed on key sociodemographic factors as well as longitudinal behavioral and clinical profiles. WWH from the Women’s Interagency HIV Study were included if they had ART data available, completed the Perceived Stress Scale-10 and PTSD Checklist-Civilian. Questionnaires...
Source: Journal of NeuroImmune Pharmacology - February 17, 2022 Category: Drugs & Pharmacology Source Type: research
Integrase Inhibitors Use for HIV Infection in Pregnancy
AbstractPurpose of ReviewThere are important unmet needs regarding HIV infection, particularly in vulnerable population, such as pregnant women and the safety and efficacy of antiretrovirals to them and their newborn. HIV integrase inhibitor agents are among the preferred antiretrovirals in most guidelines worldwide. The purpose of this review is to evaluate their safety and efficacy in that specific population.Recent FindingsAn increased importance it is being paid to this issue. However, only recently and just a few studies have been conducted trying to evaluate and compare these drugs with other agents such as efavirenz...
Source: Current Infectious Disease Reports - February 16, 2022 Category: Infectious Diseases Source Type: research
Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure
We present a case report of a neonate receiving raltegravir-based postnatal HIV prophylaxis after in utero dolutegravir exposure. High levels of raltegravir and dolutegravir can potentially cause bilirubin toxicity as they compete for albumin binding and follow the same metabolic pathway through UGT1A1. This case suggests delaying initiation of raltegravir-based postnatal prophylaxis by 24–48 hours after in utero dolutegravir exposure. (Source: The Pediatric Infectious Disease Journal)
Source: The Pediatric Infectious Disease Journal - January 19, 2022 Category: Infectious Diseases Tags: HIV Reports Source Type: research
Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial
CONCLUSION: RAL 1200 mg qd as part of a maintenance triple therapy showed a high efficacy in virologically suppressed HIV-1 infected subjects, with good safety profile and improved lipid profile and patient reported outcomes.TRIAL REGISTRATION: Clinical trials.gov NCT03195452 and EudraCT 2016-003702-13.PMID:35033092 | DOI:10.1186/s12981-022-00428-5 (Source: AIDS Research and Therapy)
Source: AIDS Research and Therapy - January 16, 2022 Category: Infectious Diseases Authors: Nolwenn Hall Clotilde Allavena Christine Katlama Alexandra Jobert Jean-Michel Molina Eric Cua Firouz é Bani-Sadr Laurent Hocqueloux Claudine Duvivier Dominique Merrien Hitoto Hikombo Elisabeth Andr é-Garnier Aur élie Gaultier Fran çois Raffi QDISS Stu Source Type: research
Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial
CONCLUSION: RAL 1200 mg qd as part of a maintenance triple therapy showed a high efficacy in virologically suppressed HIV-1 infected subjects, with good safety profile and improved lipid profile and patient reported outcomes.TRIAL REGISTRATION: Clinical trials.gov NCT03195452 and EudraCT 2016-003702-13.PMID:35033092 | DOI:10.1186/s12981-022-00428-5 (Source: AIDS Research and Therapy)
Source: AIDS Research and Therapy - January 16, 2022 Category: Infectious Diseases Authors: Nolwenn Hall Clotilde Allavena Christine Katlama Alexandra Jobert Jean-Michel Molina Eric Cua Firouz é Bani-Sadr Laurent Hocqueloux Claudine Duvivier Dominique Merrien Hitoto Hikombo Elisabeth Andr é-Garnier Aur élie Gaultier Fran çois Raffi QDISS Stu Source Type: research
